Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss and glycemic control, often superior to other GLP-1 agents.
Tirzepatide is a once-weekly injection that helps with weight loss and blood sugar. It works by targeting two hormones. Higher doses lead to more weight loss. It is an option if other GLP-1 drugs are not enough.
GoodSupportsHIGH confidence
Tirzepatide has been found to be associated with a marked dose-dependent loss of body weight: a loss of 0.9 kg was observed with a dose of 1 mg, or 11.3 kg with a dose of 15 mg
Why this rating
Based on phase 3 trials (SURPASS, SURMOUNT).
Source
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Sanjay Kalra et al. · Diabetes Therapy · 2021
DOI 10.1007/s13300-021-01113-y
narrative_reviewCited 37×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP1RAs) produce significant weight loss and glycemic control in type 2 diabetes and obesity, with efficacy varying by specific agent, dose, and formulation.Good
- Fixed-ratio combinations of GLP-1 receptor agonists and basal insulin provide superior glycemic control and weight loss compared to insulin alone, without increasing hypoglycemia risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →